Early-Stage Esophageal Cancer Might Not Favor Endoscopic Resections
the Cancer Therapy Advisor take:
Patients with localized, early-stage esophageal cancer may undergo endoscopic esophageal resection, which uses a small camera attached to a flexible tube.
This instrument allows little to no distraction to the body while navigating to specific locations throughout the gastrointestinal tract. The surgeon then carries out an esophageal surgical resection to remove a small section of the patient’s esophagus and reconnect the remaining sections of the digestive tract.
Recently, there has been an increase of endoscopic resections over surgical resections; however, according to a study published in the Journal of the National Cancer Institute, an endoscopic resection may not be the best treatment for patients with localized, early-stage esophageal cancer. Senior author David J. Bentrem, MD, and researchers from Northwestern Medicine found that the more invasive, traditional surgical resection had an 87.6% 5-year survival rate, compared to the 76% 5-year survival rate for patients who underwent the less-invasive endoscopic resection.
Results indicated that esophageal resection increased for patients with T1a cancers from 19% in 2004 to 53% in 2010. For patients with T1b cancers, which are more mature and more likely to spread to at least one lymph node compared with T1a cancers, esophageal resection increased from 6.6% in 2004 to 20.9% in 2010.
A new study sheds light on the risks with the growing popularity of endoscopic resection.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Real-World Study Shows High Response Rates to T-VEC in Early Metastatic Melanoma
- Are Next-Gen Antibody-Drug Conjugates a Path Forward for Non-Hodgkin Lymphoma and Myeloma?
- Using ctDNA to Predict Cancer Recurrence and Guide Therapy Selection
- Ponatinib Tops Bosutinib for Third-Line Treatment of CML in a Comparative Analysis
- Plastics and Cancer
- FDA-Approved Breast Cancer Drug Treatments
- A Trained Dog Smells Early-Stage Lung Cancer With a High Degree of Accuracy
- FDA-Approved Colorectal Cancer Drug Treatments
- Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?
- Emetogenic Potential of Antineoplastic Agents
- 20-Year Data Link High-Dose Chemotherapy and Hematopoietic Stem Cell Transplant to Survival Benefit in High-Risk Early Breast Cancer
- Cabozantinib Shows Promising Activity in Osteosarcoma and Ewing Sarcoma
- Reducing Trastuzumab Duration Lowers Costs by Nearly £10,000 in HER2-positive Breast Cancer
- Resistance Mechanisms Identified for NSCLC Progression With First-Line Osimertinib
- Atezolizumab and Nab-Paclitaxel Prolonged PFS in Metastatic Triple-Negative Breast Cancer